Letter | Published:

A novel cancer therapy using a Mössbauer-isotope compound

Subjects

Abstract

Cancer radiotherapy uses high doses of ionizing radiation (l–102Gy; 102–104rad) because only a small fraction of the absorbed dose leads to lethal double-strand breaks in DNA. These breaks are more efficiently produced by Auger electrons (1–10 eV nm−1) generated in proximity to the DNA. The energy of these electrons (on average 21 electrons for the decay of 125I) is dissipated within 10–100 nm of the Auger event and produces multiple double-strand DNA breaks1,2. A single Auger event can be lethal to a cell and is comparable to more than 105 photon absorption events in conventional radiotherapy3,4. We now report that 57Fe(III).bleomycin, administered to malignant cells in vitro and in vivo and irradiated with resonant Mossbauer gamma rays (14.4 keV), causes ablation of the malignant cells, presumably by Auger cascade, with extremely small radiation doses—about 10−5 Gy. As a basis for comparison, about 5 Gy is necessary to achieve a similar effect with conventional radiotherapy5.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Charlton, D. E. & Booz, J. Radiat. Res. 87, 10–23 (1981).

  2. 2

    Linz, U. & G. Stoecklin, G. 7th International Congress of Radiation Research (Amsterdam, 1983).

  3. 3

    Hofer, K. G. & Hughes, W. L. Radiat. Res. 47, 94–109 (1971).

  4. 4

    Feinendegen, L. E., Ertl, H. H. & Bond, V. P. Proc. Symp. Biophysical Aspects of Radiation Quality 419–430 (International Atomic Energy Agency, Australia 1971).

  5. 5

    Hall, E. J. Radiology for the Radiologist 2nd edn, 225 (Harper & Row, Philadelphia, 1978).

  6. 6

    Hannon, J. P., Carron, N. J. & Trammell, G. T. Phys. Rev. B9, 2791–2809 (1974).

  7. 7

    Paoletti, J., Magee, B. B. & Magee, P. T. Biochemistry 16, 351–357 (1977).

  8. 8

    Sakai, T. T., Riordan, J. M., Booth, T. E. & Glickson, J. D. J. Med. Chem. 24, 279–285 (1981).

  9. 9

    Povirk, L. F., Hogan, M. & Dattagupta, N. Biochemistry 18, 96–101 (1979).

  10. 10

    Rao, E. A., Saryan, L. A., Antholine, W. E. & Petering, D. H. J. Med. Chem. 23, 1310–1318 (1980).

  11. 11

    Lin, P., Kwock, L., Hefter, K. & Misslbeck, G. Cancer Res. 43, 1049–1053 (1983).

  12. 12

    Wu, H., N. Dattagupta, M. Hogan & Crothers, D. M. Biochemistry 19, 626–634 (1980).

  13. 13

    Lawrence, J. & Daune, M. Biochemistry 15, 3301–3307 (1976).

  14. 14

    Lawrence, J., Chan, D. C. F. & Piette, L. H. Nucleic Acids Res. 3, 2879–2893 (1976).

  15. 15

    Paoletti, C. et al. Recent Results in Cancer Research 74, 107–122 (1980).

  16. 16

    Stecher, P. G. (ed) The Merck Index 8th edn, 6 (Merck & Co., New Jersey, 1968).

  17. 17

    Clarke, E. G. C. Isolation and Identification of Drugs Vol. 1, 366 (Pharmaceutical Press, London, 1969).

  18. 18

    Burger, R. M., Kent, T. A., Horwitz, S. B., Munck, E. & Peisach, J. J. Biol. Chem. 258, 1559–1564 (1983).

Download references

Author information

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.